Posted on 9/29/16
Pfizer: No Buy Signal After The Dip
At first glance, the multi-month drop in Pfizer (NYSE:PFE) appears to offer an opportunity. After all, the dividend is back to a respectable 3.5%.When reviewing the . . .
Posted on 9/29/16
Johnson & Johnson: Buying The Dips Beats The Drips - Timing Not An Issue
The Dilemma For Fully Invested Dividend Growth InvestorsHere's an interesting passage from a recent article by Seeking Alpha Author Gary Gordon: According to a Wealth-X census, . . .
Posted on 9/29/16
Better Buy: Johnson & Johnson vs. AbbVie
IMAGE SOURCE: GETTY IMAGES.Keeping the world healthy takes a huge amount of effort, and many of the largest companies on the planet have made it their . . .
Posted on 9/29/16
Tabula Rasa HealthCare Prices IPO
Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and
Posted on 9/28/16
Foamix Pharmaceuticals Prices $57 Million Follow-on Offering of Ordinary Shares
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today . . .
Posted on 9/28/16
Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration
VANCOUVER, British Columbia & TOKYO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Zymeworks Inc., a clinical-stage biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics including bi-specific antibodies and drug . . .
Posted on 9/28/16
DermaMed Solutions Celebrates Fifth Anniversary of Ownership of Mark Pinsley and Ginger Hodulik
Five years ago, two co-workers from a corporate background with an emphasis on employee healthcare found a small, family-owned skincare machinery manufacturer in a seemingly sleepy . . .
Posted on 9/28/16
The 3 Best-Run Companies in the Healthcare Sector
IMAGE SOURCE: GETTY IMAGES.The healthcare sector is massive and poised for long-term growth, but it's also becoming increasingly more competitive. One way investors can increase their . . .
Posted on 9/28/16
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Now that Pfizer has (NYSE:PFE) decided to call off its proposed split, all eyes are squarely focused on the pharma giant's growth prospects as a single . . .
Posted on 9/28/16
Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company
IMAGE SOURCE: GETTY IMAGES.Last week, Pfizer (NYSE:PFE) agreed to a deal with privately held biopharma company OncoImmune. It could be worth up to $250 million in . . .
Posted on 9/28/16
Pfizer's 9% Decline Gives Dividend Investors Buying Opportunity
Pfizer (NYSE:PFE) has been one of the Dow's worst performers over the past two months. Since Aug. 1, shares of the Big Pharma giant are down . . .
Posted on 9/27/16
3 Biotechs With Potential Big-Time Upside
IMAGE SOURCE: GETTY IMAGES.Investors who succeed in the small-cap biotech market have learned to temper their expectations. Only a small number of these companies succeed, and . . .
Posted on 9/27/16
Cantel Medical Expands its Direct Sales Operations in Canada
CANTEL MEDICAL CORP. (NYSE: CMN), a leading global company dedicated to delivering innovative infection prevention products and services, today announced that the Company has expanded its . . .
Posted on 9/27/16
Pharmacy Times Honors Pharmacists During American Pharmacists Month
PLAINSBORO, N.J.--(BUSINESS WIRE)--Pharmacy Times®, the leading media resource for pharmacists and the pharmacy industry, celebrates American Pharmacists Month (APhM) this October. Sponsored by the American Pharmacists . . .
Posted on 9/26/16
Cambrex To Acquire PharmaCore
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs)
Posted on 9/26/16
Snippet Roundup: Firsts For Chinese CAR Companies, Setbacks For J&J And Mast
Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items.This week, September 19-23, 2016, we had thoughts on the following: . . .
Posted on 9/26/16
3 Bold Bets on the Future of Biotechnology
IMAGE SOURCE: GETTY IMAGES.While we Fools generally invest in companies that are established and generating cash, we also recognize that there's room for speculation in almost . . .
Posted on 9/26/16
Biotech: What's Next For M&A?
"For the merchant, even honesty is a financial speculation." - Charles BaudelaireIt is hard to believe summer and the third quarter are rapidly coming to an . . .
Posted on 9/26/16
Marijuana Could Be the Key to Overcoming America's Opioid Epidemic
IMAGE SOURCE: GETTY IMAGES. America has a problem.Though prescription drugs are designed to help patients, one class of prescription drugs known as opioids, which are commonly . . .
Posted on 9/26/16
Behavioral Health Home Plus Wins 2016 Recognition of Excellence in Wellness from SAMHSA's Program
The Behavioral Health Alliance of Rural Pennsylvania (BHARP) and Community Care Behavioral Health Organization (Community Care) are pleased to announce that the Behavioral Health Home Plus . . .
Posted on 9/26/16
The Children's Hospital of Philadelphia Announces Major $50 Million Pediatric Genetics Research and Patient Care Initiative
The Children's Hospital of Philadelphia (CHOP) today announced the creation of the Roberts Collaborative for Genetics and Individualized Medicine at CHOP.The $50 million Roberts Collaborative will . . .
Posted on 9/26/16
Qfix Announces Launch of Symphony Patient Transport System
Qfix (www.Qfix.com), a world leader in radiotherapy patient positioning devices, announced it is launching the new Symphony Patient Transport System that maximizes workflow efficiencies and throughput . . .
Posted on 9/23/16
Roka Bioscience Completes Private Placement of Preferred Stock and Warrants
Roka Bioscience, Inc. (ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the completion of its . . .
Posted on 9/22/16
3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions
IMAGE SOURCE: GETTY IMAGES.Roughly 90% of drugs in clinical trials never make it to the Food and Drug Administration for review, so it's not surprising that . . .
Posted on 9/22/16
The Most Exciting Drug in Celgene's Pipeline
IMAGE SOURCE: PIXABAY.Seeing as it contributes more than 60% of total revenue, it is no surprise that $6 billion blood cancer drug Revlimid has captured the . . .
Philadelphia
